Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010
- 1 December 2010
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 10 (6), 424-442
- https://doi.org/10.3816/clml.2010.n.076
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal functionCancer, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myelomaAnnals of Hematology, 2009
- The use of novel agents in the treatment of relapsed and refractory multiple myelomaLeukemia, 2009
- Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple MyelomaTransplantation and Cellular Therapy, 2008
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myelomaLeukemia, 2008
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006